Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
about
Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infectionAntiviral treatments for lamivudine-resistant chronic hepatitis B adult patientsCurrent trends in management of hepatitis B virus reactivation in the biologic therapy eraKASL clinical practice guidelines: management of chronic hepatitis BChronic Hepatitis B with Spontaneous Severe Acute ExacerbationGenetic variation of hepatitis B virus and its significance for pathogenesisThe Role of Oxidative Stress and Antioxidants in Liver DiseasesAntiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus InfectionChange of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationAntiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesLiver safety assessment in special populations (hepatitis B, C, and oncology trials)Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsAntiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-AnalysisCurrent and future antiviral drug therapies of hepatitis B chronic infectionAntiviral drug resistance: mechanisms and clinical implicationsAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsA Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola VirusA novel estimation of the relative economic value in terms of different chronic hepatitis B treatment optionsOutcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting listManagement of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipientsEfficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.Antiviral therapy and resistance with hepatitis B virus infection.Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West AfricaClinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.A cutting-edge view on the current state of antiviral drug development.Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Individualized management of pregnant women with high hepatitis B virus DNA levels.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsChronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practiceReview of hepatitis B therapeutics.Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy.Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.
P2860
Q24185958-08EDD549-EAE1-4504-89B3-C8D0D605084EQ24241469-5011AC55-18C9-46AC-97B6-01AA6B65C618Q24634879-985CBCA9-5A21-420F-91A7-FA94254DC3C0Q26752475-6F32FA58-E862-4F32-8628-4D6FF2BB7867Q26772036-5E7F13CC-5A3B-48BA-B4E2-CEABEBC5DBC5Q26772348-8C9DBD1E-0855-4FD0-AC87-A70C7767918CQ26779146-56D4B929-B621-4428-A4EE-F8835E13B7A6Q26781962-AC2997D3-13BF-45B7-B844-F00CC2E9DB61Q26784241-E3F614DC-C3BF-4134-AEC3-3ADB069356EEQ26830435-ABEC642C-F2C0-4AA0-8513-929C0BF657A8Q27000080-455ECA48-7CA2-4272-A22F-C08A232F0141Q27008502-47914D62-584F-4716-9D0D-8DDCE26DB821Q27008984-F24FED67-9B6B-4B02-8537-8014A91D297DQ28074579-70012F7D-0426-41E0-AB0A-1C8190D55667Q28084820-97F2350B-A2E6-4016-AFDD-BF38DFC3847AQ28282376-89E1EF38-008D-4DDD-86B4-00D23B0F2DA4Q28535003-05FD6BDF-9630-49DC-85AE-52946FF877A3Q28552295-6F9072D7-2900-460C-B2F2-0D5D9797870CQ28704122-330FCF8C-CC05-4568-BEB4-0A514B2FA839Q30440211-310FC9AB-1B2C-41FA-AFFB-19EE9FDF2726Q33242705-98481247-91EF-4EA2-882D-1DD702FDB48DQ33492413-7C086824-70D8-42A8-8C2D-E51F8804CAF5Q33627472-593DDB7D-12C1-4BB0-A785-B53CE48095ABQ33718935-2353F7D2-2E9D-4E2E-A072-F5A9DB0521CEQ33787531-9BA5837D-FFAE-42E1-95CB-1A2133B864F4Q33797424-981D0D5F-041B-4B15-B07D-4838F26FD3E6Q33869365-F3F1E34E-EF8A-40DB-B532-32A348F96D46Q33869423-161B89DB-0207-4FA0-A015-714D33687188Q34017787-0EFDF94D-0C30-417E-B59B-838E63DF7BB1Q34024728-6FE0FADF-2933-4F72-887C-01330CE3ADC1Q34036018-DFCE9CDC-0744-403C-A5DE-BEED8E8E1431Q34080966-73DC02A7-FC25-414E-B24E-CE5B815A663FQ34130388-33BD9342-9DFF-4A67-AD9F-FD8FC4EDAF11Q34137291-B8EF5DA7-7092-4244-BD0B-2D5A423BB42EQ34168470-1636B214-C701-4AD5-835C-9AD233A408D8Q34223779-625A19B5-17A5-47D6-A95F-9B37FD2BD9FBQ34256062-9F17D833-52C2-4097-8BDB-CE107F4F591CQ34296410-B41813E6-0A6B-44B2-8963-A71C4D8725E2Q34303163-B252CD38-9477-4973-8BE9-4D46D6F5B2D0Q34362568-FD59FEA0-81C2-4A55-A842-443A5D70BB04
P2860
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@en
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@nl
type
label
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@en
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@nl
prefLabel
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@en
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@nl
P2093
P1433
P1476
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
@en
P2093
Anna S F Lok
Ching-Lung Lai
Dorothea A Griffiths
E Jenny Heathcote
Eugene R Schiff
Guang-Bi Yao
Jules L Dienstag
Mary Castiglia
Nancy Leung
Nancy R Little
P304
P356
10.1053/J.GASTRO.2003.09.033
P407
P577
2003-12-01T00:00:00Z